{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:35:45Z","timestamp":1768624545858,"version":"3.49.0"},"reference-count":142,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Hypertension is a significant hazardous aspect for several diseases, like cardiovascular disease, kidney failure, and brain disease. Hypertension has become the most lethal condition globally, affecting approximately 1 billion people aged around 30-79 years worldwide. In the year 2022, India was ranked 170th for men and 193rd for women for HTN diagnosis rates among 200 countries worldwide. The main risk factor for cardiac failure and stroke is hypertension. The con-ventional classes of antihypertensive medications currently available have some side effects. Pre-viously, hypertension has been discussed by various researchers using conventional drug-targeting methods such as ACE inhibitors, aldosterone inhibitors, or renin inhibitors. Recently, novel drug delivery technologies utilizing nanoparticles and new pharmacological classes like ACE2 and APA inhibitors have been studied for the medication of hypertension. In this review, we have cov-ered the epidemiology of hypertension in India, its pathophysiology, medications used in the man-agement of hypertension using nanotechnology, and antihypertensive drugs currently available in the market that are approved and patented. Finally, we have covered how hypertension can be managed with the help of smart devices and artificial intelligence (AI) for improved therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573402119666230707120846","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T06:06:40Z","timestamp":1688969200000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent Insights on Drug Delivery System in Hypertension: From Bench to Market"],"prefix":"10.2174","volume":"19","author":[{"given":"Gaurav","family":"Sharma","sequence":"first","affiliation":[{"name":"University Institute of Pharma Sciences (UIPS), Chandigarh University, Gharuan, Punjab-140413, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[{"name":"University Institute of Pharma Sciences (UIPS), Chandigarh University, Gharuan, Punjab-140413, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"Roth G.A.","year":"2018","unstructured":"Roth G.A.; Abate D.; Abate K.H.; et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018,392(10159),1736-1788","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"Kearney P.M.","year":"2005","unstructured":"Kearney P.M.; Whelton M.; Reynolds K.; Muntner P.; Whelton P.K.; He J.; Global burden of hypertension: Analysis of worldwide data. Lancet 2005,365(9455),217-223","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"Forouzanfar M.H.","year":"2017","unstructured":"Forouzanfar M.H.; Liu P.; Roth G.A.; et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017,317(2),165-182","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S0140-6736(19)30955-9","volume":"394","author":"Geldsetzer P.","year":"2019","unstructured":"Geldsetzer P.; Manne-Goehler J.; Marcus M.E.; et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1\u00b71 million adults. Lancet 2019,394(10199),652-662","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"Mills K.T.","year":"2020","unstructured":"Mills K.T.; Stefanescu A.; He J.; The global epidemiology of hypertension. Nat Rev Nephrol 2020,16(4),223-237","journal-title":"Nat Rev Nephrol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"Zhou B.","year":"2017","unstructured":"Zhou B.; Bentham J.; Di Cesare M.; et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants. Lancet 2017,389(10064),37-55","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"Chobanian A.V.","year":"2003","unstructured":"Chobanian A.V.; Bakris G.L.; Black H.R.; et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003,42(6),1206-1252","journal-title":"Hypertension"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/HYPERTENSIONAHA.117.07802","volume":"70","author":"Guzik T.J.","year":"2017","unstructured":"Guzik T.J.; Touyz R.M.; Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension 2017,70(4),660-667","journal-title":"Hypertension"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/HJH.0b013e328363e964","volume":"31","author":"O\u2019Brien E.","year":"2013","unstructured":"O\u2019Brien E.; Parati G.; Stergiou G.; et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013,31(9),1731-1768","journal-title":"J Hypertens"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"Williamson J.D.","year":"2016","unstructured":"Williamson J.D.; Supiano M.A.; Applegate W.B.; et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged \u226575 Years. JAMA 2016,315(24),2673-2682","journal-title":"JAMA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/ije\/dyy016","volume":"47","author":"Zhou B.","year":"2018","unstructured":"Zhou B.; Bentham J.; Di Cesare M.; et al. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants. Int J Epidemiol 2018,47(3),872-883i","journal-title":"Int J Epidemiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12916-017-0798-z","volume":"15","author":"Zhou B.","year":"2017","unstructured":"Zhou B.; Wang H.; Yang J.; et al. How can China benefit from the achievement of the 25\u00d725 hypertension control goal in 2025? BMC Med 2017,15(1),32","journal-title":"BMC Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/jhh.2014.125","volume":"29","author":"Anchala R.","year":"2015","unstructured":"Anchala R.; Kannuri N.K.; Pant H.; et al. Prevalence of hypertension and its association with obesity: A cross-sectional survey in urban and rural Rajasthan. J Hum Hypertens 2015,29(9),592-599","journal-title":"J Hum Hypertens"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/S0140-6736(17)32804-0","volume":"390","author":"Dandona L.","year":"2017","unstructured":"Dandona L.; Dandona R.; Kumar G.A.; Nations within a nation: variations in epidemiological transition across the states of India, 1990\u20132016 in the Global Burden of Disease Study. Lancet et al. India State-Level Disease Burden Initiative Collaborators2017,390(10111),2437-2460","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/HJH.0000000000000146","volume":"32","author":"Anchala R.","year":"2014","unstructured":"Anchala R.; Kannuri N.K.; Pant H.; et al. Hypertension in India. J Hypertens 2014,32(6),1170-1177","journal-title":"J Hypertens"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ihj.2014.04.002","volume":"66","author":"Mohanan P.P.","year":"2014","unstructured":"Mohanan P.P.; Cardiology blooms at ACC 2014 at Washington DC but no cherry blossoms. Indian Heart J 2014,66(2),253-254","journal-title":"Indian Heart J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.jhh.1001984","volume":"20","author":"Thankappan K.R.","year":"2006","unstructured":"Thankappan K.R.; Shah B.; Mathur P.; Sarma P.S.; Srinivas G.; Mini G.K.; Prevalence, awareness, treatment, and control of hypertension in a rural population in South India. J Hum Hypertens 2006,20(5),383-387","journal-title":"J Hum Hypertens"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/jhh.2014.57","volume":"29","year":"2015","unstructured":"Prevalence of hypertension in Indian adults: Results from the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. J Hum Hypertens ICMR-INDIAB Collaborative Study Group2015,29(4),204-209","journal-title":"J Hum Hypertens"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0019-4832(04)70088-5","volume":"56","author":"Mohan B.","year":"2004","unstructured":"Mohan B.; Kumar N.; Aslam N.; et al. Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. Indian Heart J 2004,56(4),310-314","journal-title":"Indian Heart J"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"OC05","DOI":"10.7860\/JCDR\/2017\/27585.10133","volume":"11","author":"Choudhary M.","year":"2017","unstructured":"Choudhary M.; Gupta S.P.; Yadav R.; et al. Medication adherence and its association with blood pressure control among hypertensive patients attending a tertiary care hospital. J Clin Diagn Res 2017,11(7),OC05-OC08","journal-title":"J Clin Diagn Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(15)60734-3","volume":"386","author":"Kario K.","year":"2015","unstructured":"Kario K.; Essential hypertension: Pathophysiology and clinical management. Lancet 2015,386(9995),1545-1561","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"k2357","DOI":"10.1136\/bmj.k2357","volume":"362","author":"Khera R.","year":"2018","unstructured":"Khera R.; Lu Y.; Lu J.; et al. Impact of 2017 ACC\/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: Nationally representative cross sectional study. BMJ 2018,362,k2357","journal-title":"BMJ"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.24245\/mim.v34i2.2015","volume":"34","author":"Rubio-Guerra AF","year":"2018","unstructured":"Rubio-Guerra AF; New guides of American College of Cardiology\/American Heart Association hypertension for the treatment of high blood pressure. A jump in the right direction? Medicina Interna de M\u00e9xico 2018,34(2)","journal-title":"Medicina Interna de M\u00e9xico"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/HYPERTENSIONAHA.109.140186","volume":"56","author":"Joyner M.J.","year":"2010","unstructured":"Joyner M.J.; Charkoudian N.; Wallin B.G.; Sympathetic nervous system and blood pressure in humans: Individualized patterns of regulation and their implications. Hypertension 2010,56(1),10-16","journal-title":"Hypertension"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9562.1000250","volume":"5","author":"Delacroix S.","year":"2014","unstructured":"Delacroix S.; Chokka R.G.; Hypertension: Pathophysiology and treatment. J Neurol Neurophysiol 2014,5(6)","journal-title":"J Neurol Neurophysiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40620-020-00803-3","volume":"33","author":"Leoncini G.","year":"2020","unstructured":"Leoncini G.; Viazzi F.; De Cosmo S.; Russo G.; Fioretto P.; Pontremoli R.; Blood pressure reduction and RAAS inhibition in diabetic kidney disease: Therapeutic potentials and limitations. J Nephrol 2020,33(5),949-963","journal-title":"J Nephrol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3390\/ijms21062093","volume":"21","author":"Miguel-Jim\u00e9nez S.","year":"2020","unstructured":"Miguel-Jim\u00e9nez S.; Carvajal-Serna M.; Calvo S.; et al. Does melatonin exert its effect on ram sperm capacitation through nitric oxide synthase regulation? Int J Mol Sci 2020,21(6),2093","journal-title":"Int J Mol Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41440-021-00643-z","volume":"44","author":"Ghatage T.","year":"2021","unstructured":"Ghatage T.; Goyal S.G.; Dhar A.; Bhat A.; Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. Hypertens Res 2021,44(7),740-755","journal-title":"Hypertens Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1016\/j.numecd.2021.08.033","volume":"31","author":"Chen X.","year":"2021","unstructured":"Chen X.; Du J.; Wu X.; Cao W.; Sun S.; Global burden attributable to high sodium intake from 1990 to 2019. Nutr Metab Cardiovasc Dis 2021,31(12),3314-3321","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11906-019-0964-5","volume":"21","author":"Tanaka M.","year":"2019","unstructured":"Tanaka M.; Itoh H.; Hypertension as a metabolic disorder and the novel role of the gut. Curr Hypertens Rep 2019,21(8),63","journal-title":"Curr Hypertens Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.repce.2018.09.012","volume":"38","author":"Marques da Silva P.","year":"2019","unstructured":"Marques da Silva P.; Lima M.J.; Neves P.M.; Espiga de Macedo M.; Prevalence of cardiovascular risk factors and other comorbidities in patients with hypertension in Portuguese primary health care populations: The PRECISE study. Revista Portuguesa de Cardiologia 2019,38(6),427-437","journal-title":"Revista Portuguesa de Cardiologia"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00467-020-04579-3","volume":"36","author":"Litwin M.","year":"2021","unstructured":"Litwin M.; Ku\u0142aga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol 2021,36(4),825-837","journal-title":"Pediatr Nephrol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8879165","volume":"2020","author":"Chung A.A.","year":"2020","unstructured":"Chung A.A.; Millner P.R.; Accessory renal artery stenosis and secondary hypertension. Case Rep Nephrol 2020,2020,1-4","journal-title":"Case Rep Nephrol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton P.K.","year":"2018","unstructured":"Whelton P.K.; Carey R.M.; Aronow W.S.; et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018,71(6),1269-1324","journal-title":"Hypertension"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.18203\/2320-6012.ijrms20182821","volume":"6","author":"Gupta R.","year":"2018","unstructured":"Gupta R.; Malhotra A.; Malhotra P.; Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study. J Res Med Sci 2018,6(7),2380","journal-title":"J Res Med Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"CD001841","DOI":"10.1002\/14651858.CD001841.pub3","volume":"2018","author":"Wright J.M.","year":"2018","unstructured":"Wright J.M.; Musini V.M.; Gill R.; First-line drugs for hypertension. Cochrane Libr 2018,2018(4),CD001841","journal-title":"Cochrane Libr"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3126\/njdvl.v17i1.23291","volume":"17","author":"Bhusal M.","year":"2019","unstructured":"Bhusal M.; Aryal E.; Bhattarai S.; Shrestha S.B.; Rajouria A.; Iatrogenic Cushing syndrome due to application of potent topical corticosteroid: A case report. Nepal Journal of Dermatology. Venereology and Leprology 2019,17(1),73-75","journal-title":"Venereology and Leprology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ajh\/hpw030","volume":"29","author":"Roush G.C.","year":"2016","unstructured":"Roush G.C.; Sica D.A.; Diuretics for hypertension: A review and update. Am J Hypertens 2016,29(10),1130-1137","journal-title":"Am J Hypertens"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2215\/CJN.04330418","volume":"14","author":"Sinha A.D.","year":"2019","unstructured":"Sinha A.D.; Agarwal R.; Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol 2019,14(5),757-764","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"994","DOI":"10.20996\/1819-6446-2020-16-09","volume":"16","author":"Kochetkov A.I.","year":"2020","unstructured":"Kochetkov A.I.; Thiazide and thiazide-like diuretics in the treatment of arterial hypertension: Are there any differences? Ration Pharmacother Cardiol 2020,16(6),994-1001","journal-title":"Ration Pharmacother Cardiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1517\/14656566.2014.879117","volume":"15","author":"Tamargo J.","year":"2014","unstructured":"Tamargo J.; Segura J.; Ruilope L.M.; Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 2014,15(5),605-621","journal-title":"Expert Opin Pharmacother"},{"key":"ref=42","first-page":"158","volume":"9","author":"Thakur R.","year":"2021","unstructured":"Thakur R.; Sharma A.; An overview of mucoadhesive thermoreversible nasal gel. Asian J Pharm Res Dev 2021,9(4),158-168","journal-title":"Asian J Pharm Res Dev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13643-022-01890-y","volume":"11","author":"Martins V.M.","year":"2022","unstructured":"Martins V.M.; Ziegelmann P.K.; Helal L.; et al. Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: Protocol for a systematic review and network meta-analysis. Syst Rev 2022,11(1),23","journal-title":"Syst Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"CD002003","DOI":"10.1002\/14651858.CD002003.pub5","volume":"2017","author":"Wiysonge C.S.","year":"2017","unstructured":"Wiysonge C.S.; Bradley H.A.; Volmink J.; Mayosi B.M.; Opie L.H.; Beta-blockers for hypertension. Cochrane Libr 2017,2017(1),CD002003","journal-title":"Cochrane Libr"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.24843\/JFU.2020.v09.i02.p07","author":"Sari O.M.","year":"2020","unstructured":"Sari O.M.;  Studi penggunaan obat golongan beta-blocker pada pasien Rawat inap rumah sakit Ansari Saleh Banjarmasin 2020","journal-title":"Studi penggunaan obat golongan beta-blocker pada pasien Rawat inap rumah sakit Ansari Saleh Banjarmasin"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.1997.0331","author":"Kaplowitz GJ","year":"1997","unstructured":"Kaplowitz GJ; Dental management of the medically compromised patient. 1997"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0733-8651(05)70052-6","volume":"16","author":"Frishman W.H.","year":"1998","unstructured":"Frishman W.H.; Beta-adrenergic blockers. mechanism of action, pharmacokinetics, clinical indications, side effects, and contradictions. Cardiol Clin 1998,16(3),429-444","journal-title":"Cardiol Clin"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"CD012569","DOI":"10.1002\/14651858.CD012569.pub2","volume":"2020","author":"Wang G.M.","year":"2020","unstructured":"Wang G.M.; Li L.J.; Tang W.L.; Wright J.M.; Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Libr 2020,2020(10),CD012569","journal-title":"Cochrane Libr"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/nu9040316","volume":"9","author":"Daskaya-Dikmen C.","year":"2017","unstructured":"Daskaya-Dikmen C.; Yucetepe A.; Karbancioglu-Guler F.; Daskaya H.; Ozcelik B.; Angiotensin-I-converting enzyme (ACE)-inhibitory peptides from plants. Nutrients 2017,9(4),316","journal-title":"Nutrients"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.matpr.2022.05.299","volume":"68","author":"Agarwal S.","year":"2022","unstructured":"Agarwal S.; Thakur A.; Sharma A.; Development and evaluation of ketoprofen loaded floating microspheres for sustained delivery. Mater Today Proc 2022,68,647-652","journal-title":"Mater Today Proc"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3949\/ccjm.86a.18024","volume":"86","author":"Momoniat T.","year":"2019","unstructured":"Momoniat T.; Ilyas D.; Bhandari S.; ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med 2019,86(9),601-607","journal-title":"Cleve Clin J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"Meng J.","year":"2020","unstructured":"Meng J.; Xiao G.; Zhang J.; et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020,9(1),757-760","journal-title":"Emerg Microbes Infect"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2017.00286","volume":"8","author":"Godfraind T.","year":"2017","unstructured":"Godfraind T.; Discovery and development of calcium channel blockers. Front Pharmacol 2017,8,286","journal-title":"Front Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"CD003654","DOI":"10.1002\/14651858.CD003654.pub4","author":"Chen N.","year":"2010","unstructured":"Chen N.; Zhou M.; Yang M.; et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Libr 2010(8),CD003654","journal-title":"Cochrane Libr"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.22159\/ijap.2020v12i5.38639","volume":"12","author":"Sharma A.","year":"2020","unstructured":"Sharma A.; Harikumar S.L.; Quality by design approach for development and optimization of nitrendipine-loaded niosomal gel for accentuated transdermal delivery. Int J Appl Pharm 2020,12(5),181-189","journal-title":"Int J Appl Pharm"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/03639045.2020.1721527","volume":"46","author":"Sharma A.","year":"2020","unstructured":"Sharma A.; Singh A.P.; Harikumar S.L.; Development and optimization of nanoemulsion based gel for enhanced transdermal delivery of nitrendipine using box-behnken statistical design. Drug Dev Ind Pharm 2020,46(2),329-342","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.matpr.2022.05.301","volume":"68","author":"Sharma A.","year":"2022","unstructured":"Sharma A.; Sharma R.; Singh Bora K.; Harikumar S.L.; Pharmacokinetic investigation of nitrendipine encapsulated niosomal gel in rat plasma by RP-HPLC method. Mater Today Proc 2022,68,653-657","journal-title":"Mater Today Proc"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.3909\/riu0155","volume":"9","author":"Lepor H.","year":"2007","unstructured":"Lepor H.; Alpha-blockers in the treatment of benign prostatic hyperplasia: mechanism of action, efficacy, and safety. Rev Urol 2007,9(Suppl. 3),S18-S25","journal-title":"Rev Urol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/hr.2014.68","volume":"63","author":"Saruta T.","year":"2005","unstructured":"Saruta T.; The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Jpn J Clin Med 2005,63(6),952-958","journal-title":"Jpn J Clin Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jash.2016.11.007","volume":"11","author":"Mann S.J.","year":"2017","unstructured":"Mann S.J.; Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens 2017,11(1),54-65","journal-title":"J Am Soc Hypertens"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12884-020-03475-w","volume":"20","author":"Mulder E.","year":"2020","unstructured":"Mulder E.; Ghossein-Doha C.; Appelman E.; et al. Study protocol for the randomized controlled EVA (early vascular adjustments) trial: tailored treatment of mild hypertension in pregnancy to prevent severe hypertension and preeclampsia. BMC Pregnancy Childbirth 2020,20(1),775","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10557-016-6668-z","volume":"30","author":"Tarkin J.M.","year":"2016","unstructured":"Tarkin J.M.; Kaski J.C.; Vasodilator therapy: Nitrates and nicorandil. Cardiovasc Drugs Ther 2016,30(4),367-378","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"450","DOI":"10.5694\/j.1326-5377.1985.tb113448.x","volume":"142","author":"Kincaid-Smith P.","year":"1985","unstructured":"Kincaid-Smith P.; Vasodilator drugs in the treatment of hypertension. Med J Aust 1985,142(8),450-453","journal-title":"Med J Aust"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/VHRM.S13779","volume":"7","author":"Nappi J.","year":"2011","unstructured":"Nappi J.; Sieg A.; Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag 2011,7(1),353-363","journal-title":"Vasc Health Risk Manag"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"166037","DOI":"10.1016\/j.bbadis.2020.166037","volume":"1867","author":"Gao Q.","year":"2021","unstructured":"Gao Q.; Xu L.; Cai J.; New drug targets for hypertension: A literature review. Biochim Biophys Acta Mol Basis Dis 2021,1867(3),166037","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00467-013-2716-0","volume":"29","author":"Nadeem S.","year":"2014","unstructured":"Nadeem S.; Batisky D.L.; Aliskiren, the first direct renin inhibitor: Assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol 2014,29(11),2105-2111","journal-title":"Pediatr Nephrol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"115466","DOI":"10.1016\/j.bmc.2020.115466","volume":"28","author":"Ramya K.","year":"2020","unstructured":"Ramya K.; Suresh R.; Kumar H.Y.; Kumar B.R.P.; Murthy N.B.S.; Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. Bioorg Med Chem 2020,28(10),115466","journal-title":"Bioorg Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.12703\/b\/9-4","volume":"9","author":"Leontsinis I.","year":"2020","unstructured":"Leontsinis I.; Mantzouranis M.; Tsioufis P.; Andrikou I.; Tsioufis C.; Recent advances in managing primary hypertension. Fac Rev 2020,9,4","journal-title":"Fac Rev"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/gutjnl-2019-319300","volume":"69","author":"Szeto C.C.","year":"2020","unstructured":"Szeto C.C.; Sugano K.; Wang J.G.; et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: Joint APAGE\/APLAR\/APSDE\/APSH\/APSN\/PoA recommendations. Gut 2020,69(4),617-629","journal-title":"Gut"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11906-019-0949-4","volume":"21","author":"Kitt J.","year":"2019","unstructured":"Kitt J.; Fox R.; Tucker K.L.; McManus R.J.; New approaches in hypertension management: A review of current and developing technologies and their potential impact on hypertension care. Curr Hypertens Rep 2019,21(6),44","journal-title":"Curr Hypertens Rep"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.mtadv.2021.100198","volume":"13","author":"Adetunji C.O.","year":"2022","unstructured":"Adetunji C.O.; Michael O.S.; Rathee S.; et al. Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight. Materials Today Advances 2022,13,100198","journal-title":"Materials Today Advances"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","volume":"116","author":"Oparil S.","year":"2015","unstructured":"Oparil S.; Schmieder R.E.; New approaches in the treatment of hypertension. Circ Res 2015,116(6),1074-1095","journal-title":"Circ Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4236\/anp.2017.63008","volume":"6","author":"Jackson T.C.","year":"2017","unstructured":"Jackson T.C.; Patani B.O.; Ekpa D.E.; Nanotechnology in diagnosis: A review. Adv Nanopart 2017,6(3),93-102","journal-title":"Adv Nanopart"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11906-018-0890-y","volume":"20","author":"Davis J.","year":"2018","unstructured":"Davis J.; Oparil S.; Novel medical treatments for hypertension and related comorbidities. Curr Hypertens Rep 2018,20(10),90","journal-title":"Curr Hypertens Rep"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.22376\/ijpbs\/lpr.2022.12.5.P68-84","volume":"12","author":"Sharma A.","year":"2022","unstructured":"Sharma A.; Babu Sharma R.; Verma A.; Thakur R.; Insight on nanoparticles, green synthesis and applications in drug delivery system-a comprehensive review. Int J Life Sci Pharma Res 2022,12(5),68-84","journal-title":"Int J Life Sci Pharma Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1166\/jbn.2022.3413","volume":"18","author":"Zhang Y.","year":"2022","unstructured":"Zhang Y.; Wang Q.; Li H.; et al. Design and evaluation of a biodegradable PLGA-based nanosuspension for the delivery of an anti-cancer agent. J Biomed Nanotechnol 2022,18,660","journal-title":"J Biomed Nanotechnol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.partic.2022.02.001","volume":"64","author":"Li Y.","year":"2022","unstructured":"Li Y.; Wang L.; Li Y.; et al. Preparation and characterization of chitosan-coated magnetic nanoparticles for drug delivery applications. Particuology 2022,64,153","journal-title":"Particuology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/0975-1483.83765","volume":"3","author":"Ekambaram P.","year":"2011","unstructured":"Ekambaram P.; Abdul Hasan Sathali A.; Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011,3(3),216-220","journal-title":"J Young Pharm"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejpb.2016.04.001","volume":"103","author":"Chonkar A.D.","year":"2016","unstructured":"Chonkar A.D.; Rao J.V.; Managuli R.S.; et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation. Eur J Pharm Biopharm 2016,103,179-191","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3390\/pharmaceutics13122134","volume":"13","author":"Kara A.","year":"2021","unstructured":"Kara A.; Vassiliadou A.; Ongoren B.; et al. Engineering 3d printed microfluidic chips for the fabrication of nanomedicines. Pharmaceutics 2021,13(12),2134","journal-title":"Pharmaceutics"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bjid.2018.02.001","volume":"22","author":"Choudhary R.","year":"2018","unstructured":"Choudhary R.; Bodla R.B.; Gupta G.; et al. Nanoparticle-based drug delivery systems: promising approaches against infections. Braz J Infect Dis 2018,22(2),86-99","journal-title":"Braz J Infect Dis"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(17)34307-3","volume":"69","author":"Prajapati J.B.","year":"2018","unstructured":"Prajapati J.B.; Katariya H.; Patel R.; Peyer\u2019e patch targeting of isradipine loaded Solid Lipid Nanoparticles: it\u2019s cellular uptake study. Journal of Drug Delivery ADVERSE EVENTS: A SYSTEMATIC META-ANALYSIS. J Am Coll Cardiol 2018,69(11)","journal-title":"J Am Coll Cardiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10717544.2014.914986","volume":"23","author":"Dudhipala N.","year":"2016","unstructured":"Dudhipala N.; Veerabrahma K.; Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2016,23(2),395-404","journal-title":"Drug Deliv"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1016\/j.matpr.2022.11.221","author":"Sharma A.","year":"2022","unstructured":"Sharma A.; Thakur R.; Sharma R.; Development and optimization of candesartan cilexetil nasal gel for accentuated intranasal delivery using central composite design. Mater Today Proc In Press2022","journal-title":"Mater Today Proc"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"s117","DOI":"10.5530\/ijper.54.2s.68","volume":"54","author":"Shirisha S.","year":"2020","unstructured":"Shirisha S.; Saraswathi A.; Sahoo S.K.; Rao Y.M.; Formulation and evaluation of nisoldipine loaded solid lipid nanoparticles and nanostructured lipid carriers: application to transdermal delivery. Indian J Pharm Educ Res 2020,54(2s),s117-s127","journal-title":"Indian J Pharm Educ Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jddst.2015.11.001","volume":"31","author":"Suthar V.","year":"2016","unstructured":"Suthar V.; Butani S.; Gohel M.; Solid self-emulsified nanostructures of Lercanidipine hydrochloride: A potential approach to improve the fraction of the dose absorbed. J Drug Deliv Sci Technol 2016,31,11-21","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/adt.2021.084","volume":"20","author":"Kataria D.","year":"2022","unstructured":"Kataria D.; Zafar A.; Ali J.; et al. Formulation of lipid-based nanocarriers of lacidipine for improvement of oral delivery: box-Behnken design optimization, in vitro, ex vivo, and preclinical assessment. Assay Drug Dev Technol 2022,20(1),5-21","journal-title":"Assay Drug Dev Technol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3109\/03639045.2010.550050","volume":"37","author":"Chhabra G.","year":"2011","unstructured":"Chhabra G.; Chuttani K.; Mishra A.K.; Pathak K.; Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 2011,37(8),907-916","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejpb.2006.10.014","volume":"66","author":"Shafiq S.","year":"2007","unstructured":"Shafiq S.; Shakeel F.; Talegaonkar S.; Ahmad F.J.; Khar R.K.; Ali M.; Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007,66(2),227-243","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10717544.2016.1255999","volume":"24","author":"Alam T.","year":"2017","unstructured":"Alam T.; Khan S.; Gaba B.; Haider M.F.; Baboota S.; Ali J.; Nanocarriers as treatment modalities for hypertension. Drug Deliv 2017,24(1),358-369","journal-title":"Drug Deliv"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"313","DOI":"10.32383\/appdr\/99526","volume":"76","author":"Abu-Huwaij R.","year":"2019","unstructured":"Abu-Huwaij R.; Hamed R.; Daoud E.; Alkilani A.; Development and in vitro characterization of nanoemulsion-based buccal patches of valsartan. Acta Pol Pharm 2019,76(2),313-321","journal-title":"Acta Pol Pharm"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.colsurfb.2013.12.016","volume":"115","author":"Gorain B.","year":"2014","unstructured":"Gorain B.; Choudhury H.; Kundu A.; et al. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf B Biointerfaces 2014,115,286-294","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.31351\/vol29iss1pp41-54","volume":"29","author":"Dahash R.A.A.","year":"2020","unstructured":"Dahash R.A.A.; Rajab N.A.; Formulation and investigation of lacidipine as nanoemulsions. Iraqi J Pharm Sci 2020,29(1),41-54","journal-title":"Iraqi J Pharm Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12247-018-9319-z","volume":"13","author":"Fernandes G.J.","year":"2018","unstructured":"Fernandes G.J.; Kumar L.; Sharma K.; Tunge R.; Rathnanand M.; A review on solubility enhancement of carvedilol-a BCS Class II drug. J Pharm Innov 2018,13(3),197-212","journal-title":"J Pharm Innov"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijpharm.2014.06.048","volume":"472","author":"ElKasabgy N.A.","year":"2014","unstructured":"ElKasabgy N.A.; Elsayed I.; Elshafeey A.H.; Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: In-vitro and in-vivo characterization. Int J Pharm 2014,472(1-2),369-379","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1124\/jpet.117.246272","volume":"365","author":"Burkey B.F.","year":"2018","unstructured":"Burkey B.F.; Hoglen N.C.; Inskeep P.; Wyman M.; Hughes T.E.; Vath J.E.; Preclinical efficacy and safety of the novel antidiabetic, antiobesity metap2 inhibitor ZGN-1061. J Pharmacol Exp Ther 2018,365(2),301-313","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/DDDT.S77761","volume":"10","author":"Seth M.","year":"2016","unstructured":"Seth M.; Hussain M.E.; Pasha S.; Fahim M.; Effects of a novel ACE inhibitor, 3-(3-thienyl)-L-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in L-NAME-induced hypertensive rats. Drug Des Devel Ther 2016,10,1533-1542","journal-title":"Drug Des Devel Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/01.prs.0000465511.62305.6c","volume":"135","author":"Wilson A.J.","year":"2015","unstructured":"Wilson A.J.; Chang B.; Chin B.C.; Taglinenti A.J.; Folsom N.; Percec I.; Abstract 63: A quantitative analysis of different botulinum toxin formulations: A randomized double blind prospective clinical trial of comparative dynamic strain reduction. Plast Reconstr Surg 2015,135,50-51","journal-title":"Plast Reconstr Surg"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fphar.2016.00532","volume":"7","author":"Kim H.K.","year":"2017","unstructured":"Kim H.K.; Hwang S.H.; Abdi S.; Tempol ameliorates and prevents mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain. Front Pharmacol 2017,7(JAN),532","journal-title":"Front Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0735-1097(19)32319-8","volume":"73","author":"Dzhoyashvili N.","year":"2019","unstructured":"Dzhoyashvili N.; Iyer S.; Chen Y.; et al. The novel GC-A\/CGMP activating designer M-ATRIAL natriuretic peptide potently reduces blood pressure in a genetic model of hypertension and potentiates the actions of furosemide. J Am Coll Cardiol 2019,73(9),1713","journal-title":"J Am Coll Cardiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"ehaa946.1224","DOI":"10.1093\/ehjci\/ehaa946.1224","volume":"41","author":"Pozdnyakov Y","year":"2020","unstructured":"Pozdnyakov Y; Kostyukova A; Khokhlov A; et al. Novel soluble guanylyl cyclase activator for the treatment of hypertension and metabolic syndrome. Eur Heart J 2020,41(Suppl_2),ehaa946.1224","journal-title":"Eur Heart J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11906-021-01163-4","volume":"23","author":"Nesbitt S.D.","year":"2021","unstructured":"Nesbitt S.D.; Firibastat: A novel treatment for hypertension. Curr Hypertens Rep 2021,23(12),46","journal-title":"Curr Hypertens Rep"},{"key":"ref=103","doi-asserted-by":"publisher","DOI":"10.14744\/ejmo.2020.47992","author":"Barone M.","year":"2020","unstructured":"Barone M.;  Recombinant human angiotensin-converting enzyme 2 and COVID-19 acute respiratory distress syndrome: A theoretical or a real resource? 2020","journal-title":"Recombinant human angiotensin-converting enzyme 2 and COVID-19 acute respiratory distress syndrome: A theoretical or a real resource?"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-019-05062-x","volume":"63","author":"Hanrahan J.P.","year":"2020","unstructured":"Hanrahan J.P.; Seferovic J.P.; Wakefield J.D.; et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia 2020,63(4),733-743","journal-title":"Diabetologia"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12974-018-1262-x","volume":"15","author":"Ahmed H.A.","year":"2018","unstructured":"Ahmed H.A.; Ishrat T.; Pillai B.; et al. RAS modulation prevents progressive cognitive impairment after experimental stroke: A randomized, blinded preclinical trial. J Neuroinflammation 2018,15(1),229","journal-title":"J Neuroinflammation"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-017-0614-0","volume":"38","author":"Rosenbaum D.P.","year":"2018","unstructured":"Rosenbaum D.P.; Yan A.; Jacobs J.W.; Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor Tenapanor: two trials in healthy volunteers. Clin Drug Investig 2018,38(4),341-351","journal-title":"Clin Drug Investig"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s40265-019-01215-9","volume":"79","author":"Markham A.","year":"2019","unstructured":"Markham A.; Tenapanor: First Approval. Drugs 2019,79(17),1897-1903","journal-title":"Drugs"},{"key":"ref=108","doi-asserted-by":"publisher","DOI":"10.4018\/978-1-5225-2092-4.ch001","author":"Mathews J.L.","year":"2017","unstructured":"Mathews J.L.; Schweighardt A.; The role of natriuretic peptides in the pathophysiology and treatment of heart failure. In: Emerging applications, perspectives, and discoveries in cardiovascular research 2017","journal-title":"In: Emerging applications, perspectives, and discoveries in cardiovascular research"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","volume":"363","author":"Massie B.M.","year":"2010","unstructured":"Massie B.M.; O\u2019Connor C.M.; Metra M.; et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010,363(15),1419-1428","journal-title":"N Engl J Med"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/jcm9030824","volume":"9","author":"Enevoldsen F.C.","year":"2020","unstructured":"Enevoldsen F.C.; Sahana J.; Wehland M.; Grimm D.; Infanger M.; Kr\u00fcger M.; Endothelin receptor antagonists: Status quo and future perspectives for targeted therapy. J Clin Med 2020,9(3),824","journal-title":"J Clin Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e00619","DOI":"10.1002\/prp2.619","volume":"8","author":"Treiber A.","year":"2020","unstructured":"Treiber A.; Delahaye S.; Seeland S.; Gnerre C.; The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross\u2010species comparison of its cytochrome P450 induction pattern. Pharmacol Res Perspect 2020,8(4),e00619","journal-title":"Pharmacol Res Perspect"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00228-014-1755-8","volume":"70","author":"Sidharta P.N.","year":"2014","unstructured":"Sidharta P.N.; van Giersbergen P.L.; Halabi A.; Dingemanse J.; Macitentan: Entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2014,70(12),1479-1486","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s40262-021-01049-3","volume":"60","author":"Bartolucci R.","year":"2021","unstructured":"Bartolucci R.; Dosne A.G.; Csonka D.; P\u00e9rez-Ruixo J.J.; Magni P.; Poggesi I.; A population pharmacokinetic model of macitentan and its active metabolite Aprocitentan in healthy volunteers and patients with pulmonary arterial hypertension. Clin Pharmacokinet 2021,60(12),1605-1619","journal-title":"Clin Pharmacokinet"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fphar.2020.00433","volume":"11","author":"Wei C.Y.","year":"2020","unstructured":"Wei C.Y.; Tzeng I.S.; Lin M.C.; Yeh Y.H.; Hsu C.Y.; Kung W.M.; Risks of sulpiride-induced Parkinsonism in peptic ulcer and gastroesophageal reflux disease patients in Taiwan: A nationwide population-based study. Front Pharmacol 2020,11,433","journal-title":"Front Pharmacol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4161\/hv.27520","volume":"10","author":"Bairwa M.","year":"2014","unstructured":"Bairwa M.; Pilania M.; Gupta V.; Yadav K.; Hypertension Vaccine may be a boon to millions in developing world. Hum Vaccin Immunother 2014,10(3),708-713","journal-title":"Hum Vaccin Immunother"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2009.06.003","volume":"134","author":"Maurer P.","year":"2010","unstructured":"Maurer P.; Bachmann M.F.; Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010,134(1),89-95","journal-title":"Clin Immunol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","volume":"8","author":"Oliva R.V.","year":"2014","unstructured":"Oliva R.V.; Bakris G.L.; Blood pressure effects of sodium\u2013glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014,8(5),330-339","journal-title":"J Am Soc Hypertens"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"91","DOI":"10.14423\/SMJ.0000000000000235","volume":"108","author":"Mikhail N.","year":"2015","unstructured":"Mikhail N.; Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J 2015,108(2),91-96","journal-title":"South Med J"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/jop.2014.0114","volume":"31","author":"Sharif N.A.","year":"2015","unstructured":"Sharif N.A.; Novel potential treatment modalities for ocular hypertension: Focus on angiotensin and bradykinin system axes. J Ocul Pharmacol Ther 2015,31(3),131-145","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.yjmcc.2019.03.024","volume":"130","author":"Chen Y.","year":"2019","unstructured":"Chen Y.; Zheng Y.; Iyer S.R.; et al. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. J Mol Cell Cardiol 2019,130,140-150","journal-title":"J Mol Cell Cardiol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1254\/fpj.20016","volume":"155","author":"Yamakawa S.","year":"2020","unstructured":"Yamakawa S.; Homma T.; Yamada M.; Igawa Y.; Yoshimura M.; Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro<sup>\u00ae<\/sup> tablets 1.25 mg, 2.5 mg, 5 mg). Nippon Yakurigaku Zasshi 2020,155(5),340-350","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"105597","DOI":"10.1016\/j.ejps.2020.105597","volume":"156","author":"Pezik E.","year":"2021","unstructured":"Pezik E.; Gulsun T.; Sahin S.; Vural \u0130 Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. Eur J Pharm Sci 2021,156,105597","journal-title":"Eur J Pharm Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"e000473","DOI":"10.1136\/openhrt-2016-000473","volume":"3","author":"Fares H.","year":"2016","unstructured":"Fares H.; DiNicolantonio J.J.; O\u2019Keefe J.H.; Lavie C.J.; Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart 2016,3(2),e000473","journal-title":"Open Heart"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10557-020-07054-1","volume":"35","author":"Ma W.","year":"2021","unstructured":"Ma W.; Sun N.; Duan C.; et al. Effectiveness of Levoamlodipine maleate for hypertension compared with amlodipine besylate: a pragmatic comparative effectiveness study. Cardiovasc Drugs Ther 2021,35(1),41-50","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"n\/a","DOI":"10.1111\/bph.12824","volume":"171","author":"Snelder N","year":"2014","unstructured":"Snelder N; Ploeger BA; Luttringer O; et al. Drug effects on the CVS in conscious rats: Separating cardiac output into heart rate and stroke volume using PKPD modelling. Br J Pharmacol 2014,171(22),n\/a","journal-title":"Br J Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1177\/0300060518788994","volume":"46","author":"Saputri F.A.","year":"2018","unstructured":"Saputri F.A.; Kang D.; Kusuma A.S.W.; et al. Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. J Int Med Res 2018,46(12),5004-5010","journal-title":"J Int Med Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10928-018-9574-0","volume":"45","author":"Mukherjee D.","year":"2018","unstructured":"Mukherjee D.; Zha J.; Menon R.M.; Shebley M.; Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic\/pharmacodynamic model. J Pharmacokinet Pharmacodyn 2018,45(3),443-456","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jpha.2012.03.002","volume":"2","author":"Mahmoud A.M.","year":"2012","unstructured":"Mahmoud A.M.; Abdel-Wadood H.M.; Mohamed N.A.; Kinetic spectrophotometric method for determination of amlodipine besylate in its pharmaceutical tablets. J Pharm Anal 2012,2(5),334-341","journal-title":"J Pharm Anal"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1085\/jgp.93.6.1109","volume":"93","author":"Kass R.S.","year":"1989","unstructured":"Kass R.S.; Arena J.P.; Influence of pHo on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor. J Gen Physiol 1989,93(6),1109-1127","journal-title":"J Gen Physiol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"200181","DOI":"10.1183\/16000617.0181-2020","volume":"29","author":"Khemasuwan D.","year":"2020","unstructured":"Khemasuwan D.; Sorensen J.S.; Colt H.G.; Artificial intelligence in pulmonary medicine: Computer vision, predictive model and COVID-19. Eur Respir Rev 2020,29(157),200181","journal-title":"Eur Respir Rev"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11906-020-01068-8","volume":"22","author":"Mueller F.B.","year":"2020","unstructured":"Mueller F.B.; AI (artificial intelligence) and hypertension research. Curr Hypertens Rep 2020,22(9),70","journal-title":"Curr Hypertens Rep"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10796-021-10142-8","volume":"\u2022","author":"Fosso Wamba S.","year":"2021","unstructured":"Fosso Wamba S.; Queiroz M.M.; Responsible artificial intelligence as a secret ingredient for digital health: Bibliometric analysis, insights, and research directions. Inf Syst Front 2021,\u2022,1-16","journal-title":"Inf Syst Front"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"100027","DOI":"10.1016\/j.ijchy.2020.100027","volume":"5","author":"Amaratunga D.","year":"2020","unstructured":"Amaratunga D.; Cabrera J.; Sargsyan D.; Kostis J.B.; Zinonos S.; Kostis W.J.; Uses and opportunities for machine learning in hypertension research. Int J Cardiol Hypertens 2020,5,100027","journal-title":"Int J Cardiol Hypertens"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11906-018-0875-x","volume":"20","author":"Krittanawong C.","year":"2018","unstructured":"Krittanawong C.; Bomback A.S.; Baber U.; Bangalore S.; Messerli F.H.; Wilson Tang W.H.; Future direction for using artificial intelligence to predict and manage hypertension. Curr Hypertens Rep 2018,20(9),75","journal-title":"Curr Hypertens Rep"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41440-020-0498-x","volume":"43","author":"Koshimizu H.","year":"2020","unstructured":"Koshimizu H.; Kojima R.; Okuno Y.; Future possibilities for artificial intelligence in the practical management of hypertension. Hypertens Res 2020,43(12),1327-1337","journal-title":"Hypertens Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/09720529.2019.1637156","volume":"22","author":"Andrews L.J.B.","year":"2019","unstructured":"Andrews L.J.B.; Raja L.; Shanmugasundaram S.; Mobile android-based remote patient monitoring system through wearable sensors. J Discrete Math Sci Cryptogr 2019,22(4),557-568","journal-title":"J Discrete Math Sci Cryptogr"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1016\/S0735-1097(20)34210-8","volume":"75","author":"Adhikary R.","year":"2020","unstructured":"Adhikary R.; Krishnakumar A.; Kolwankar S.; Shah A.; Sanghavi S.; Mattoo V.; Effectiveness of digital therapeutics to improve blood pressure control among patients with hypertension and diabetes in India. J Am Coll Cardiol 2020,75(11),3583","journal-title":"J Am Coll Cardiol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1109\/JBHI.2020.3021532","volume":"25","author":"Ganti V.G.","year":"2021","unstructured":"Ganti V.G.; Carek A.M.; Nevius B.N.; Heller J.A.; Etemadi M.; Inan O.T.; Wearable cuff-less blood pressure estimation at home via pulse transit time. IEEE J Biomed Health Inform 2021,25(6),1926-1937","journal-title":"IEEE J Biomed Health Inform"},{"key":"ref=139","doi-asserted-by":"publisher","DOI":"10.3837\/tiis.2022.01.010","volume":"16","author":"Alotaibi M.","year":"2022","unstructured":"Alotaibi M.; Uddin M.A.; Effectiveness of e-health systems in improving hypertension management and awareness: A systematic review. Trans Internet Inf Syst 2022,16(1)","journal-title":"Trans Internet Inf Syst"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1109\/RBME.2017.2769423","volume":"10","author":"Majumder S.","year":"2017","unstructured":"Majumder S.; Wearable sensors for monitoring of physiological parameters and algorithms for extraction of clinically relevant information. IEEE Rev Biomed Eng 2017,10,86-99","journal-title":"IEEE Rev Biomed Eng"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12911-019-0874-0","volume":"19","author":"Elshawi R.","year":"2019","unstructured":"Elshawi R.; Al-Mallah M.H.; Sakr S.; On the interpretability of machine learning-based model for predicting hypertension. BMC Med Inform Decis Mak 2019,19(1),146","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1001\/jama.2016.17438","volume":"316","author":"Jha S.","year":"2016","unstructured":"Jha S.; Topol E.J.; Adapting to artificial intelligence: Radiologists and pathologists as information specialists. JAMA 2016,316(22),2353-2354","journal-title":"JAMA"}],"container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573402119666230707120846","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218520\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573402119666230707120846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:42:54Z","timestamp":1696333374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218520\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402119666230707120846","relation":{},"ISSN":["1573-4021"],"issn-type":[{"value":"1573-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}